Zhejiang Tianyu Pharmaceutical Co Ltd Cash Flow Conversion Efficiency
Zhejiang Tianyu Pharmaceutical Co Ltd cash flow conversion efficiency. Based on the latest financial reports, Zhejiang Tianyu Pharmaceutical Co Ltd (300702) has a cash flow conversion efficiency ratio of 0.063x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥233.18 Million ≈ $34.12 Million USD) by net assets (CN¥3.72 Billion ≈ $544.40 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Zhejiang Tianyu Pharmaceutical Co Ltd (2013–2025)
Cash flow conversion efficiency of Zhejiang Tianyu Pharmaceutical Co Ltd from 2013 to 2025. This chart illustrates how Zhejiang Tianyu Pharmaceutical Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. View latest Zhejiang Tianyu Pharmaceutical Co Ltd stock price today for real-time trading data and today's change.
Zhejiang Tianyu Pharmaceutical Co Ltd Cash Flow Conversion Ratio Explained
Zhejiang Tianyu Pharmaceutical Co Ltd cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Zhejiang Tianyu Pharmaceutical Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Zhejiang Tianyu Pharmaceutical Co Ltd ranked by their cash flow conversion efficiency. Also see Zhejiang Tianyu Pharmaceutical Co Ltd stock valuation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Idorsia Ltd
SW:IDIA
|
0.023x |
|
Ningbo Menovo Pharm Co Ltd
SHG:603538
|
0.013x |
|
Grupo Herdez S.A.B. de C.V
MX:HERDEZ
|
-0.014x |
|
Guangdong CHJ Industry Co Ltd
SHE:002345
|
-0.164x |
|
Coretronic
TWO:5371
|
-0.004x |
|
Baltic Classifieds Group PLC
LSE:BCG
|
0.103x |
|
Pegavision
TW:6491
|
0.067x |
|
Atlas Energy Solutions Inc.
NYSE:AESI
|
0.016x |
Annual Cash Flow Conversion Efficiency for Zhejiang Tianyu Pharmaceutical Co Ltd (2013–2025)
The table below shows the annual cash flow conversion efficiency of Zhejiang Tianyu Pharmaceutical Co Ltd from 2013 to 2025. Review how much free cash does Zhejiang Tianyu Pharmaceutical Co Ltd generate to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CN¥3.64 Billion ≈ $532.59 Million |
CN¥473.57 Million ≈ $69.30 Million |
0.130x | +32.05% |
| 2024-12-31 | CN¥3.50 Billion ≈ $511.83 Million |
CN¥344.64 Million ≈ $50.43 Million |
0.099x | +882.72% |
| 2023-12-31 | CN¥3.49 Billion ≈ $510.37 Million |
CN¥-43.90 Million ≈ $-6.42 Million |
-0.013x | +9.66% |
| 2022-12-31 | CN¥3.50 Billion ≈ $511.43 Million |
CN¥-48.70 Million ≈ $-7.13 Million |
-0.014x | +80.29% |
| 2021-12-31 | CN¥3.71 Billion ≈ $542.77 Million |
CN¥-262.23 Million ≈ $-38.37 Million |
-0.071x | -140.30% |
| 2020-12-31 | CN¥3.55 Billion ≈ $519.00 Million |
CN¥622.18 Million ≈ $91.04 Million |
0.175x | -16.47% |
| 2019-12-31 | CN¥2.04 Billion ≈ $298.10 Million |
CN¥427.84 Million ≈ $62.61 Million |
0.210x | +286.63% |
| 2018-12-31 | CN¥1.45 Billion ≈ $211.66 Million |
CN¥78.57 Million ≈ $11.50 Million |
0.054x | -20.98% |
| 2017-12-31 | CN¥1.29 Billion ≈ $188.43 Million |
CN¥88.52 Million ≈ $12.95 Million |
0.069x | -74.66% |
| 2016-12-31 | CN¥607.31 Million ≈ $88.87 Million |
CN¥164.74 Million ≈ $24.11 Million |
0.271x | +811.67% |
| 2015-12-31 | CN¥495.77 Million ≈ $72.55 Million |
CN¥14.75 Million ≈ $2.16 Million |
0.030x | -83.12% |
| 2014-12-31 | CN¥456.22 Million ≈ $66.76 Million |
CN¥80.44 Million ≈ $11.77 Million |
0.176x | +101.33% |
| 2013-12-31 | CN¥453.68 Million ≈ $66.39 Million |
CN¥39.73 Million ≈ $5.81 Million |
0.088x | -- |
About Zhejiang Tianyu Pharmaceutical Co Ltd
Zhejiang Tianyu Pharmaceutical Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceutical intermediates and APIs in China and internationally. The company offers pharmaceutical intermediates and APIs of anti-hypertensive, anti-allergic, anticancer, anti-fungal, anti-epileptic, anti-asthmatic, hypoglycemic, hypolipidemic, and anticoagulant series. It also provides fine… Read more